Dystroglycan complex in cancer

Eur J Surg Oncol. 2004 Aug;30(6):589-92. doi: 10.1016/j.ejso.2004.03.014.

Abstract

Abnormalities in the interactions between tumour cells, adhesion molecules and extracellular matrix proteins are often implicated in the behaviour of carcinoma cells. The alpha- and beta-dystroglycan (DG) proteins form part of the large dystrophin-associated protein (DAP) complex. They are involved in epithelial cell development, formation of the basement membrane and maintenance of tissue integrity. Specific changes and reduction or loss of DG expression have been reported in human breast, colon, head and neck, and prostate cancers, implicating it in tumour invasion and dissemination. Degradation of beta-DG by matrix metalloproteinase (MMP) enzymes may assist tumour dissemination. We report the present knowledge of the DG interactions in solid tumour biology.

Publication types

  • Review

MeSH terms

  • Cytoskeletal Proteins / metabolism*
  • Dystroglycans
  • Humans
  • Matrix Metalloproteinases / metabolism
  • Membrane Glycoproteins / metabolism*
  • Neoplasm Invasiveness / physiopathology
  • Neoplasm Metastasis / physiopathology
  • Neoplasms / metabolism*
  • Neoplasms / pathology
  • Neoplasms / physiopathology

Substances

  • Cytoskeletal Proteins
  • DAG1 protein, human
  • Membrane Glycoproteins
  • Dystroglycans
  • Matrix Metalloproteinases